The Fatty Acid Synthase Inhibitor Platensimycin Improves Insulin Resistance without Inducing Liver Steatosis in Mice and Monkeys

• Published in: PloS one Vol. 11; no. 10; p. e0164133
• Main Authors: Singh, Sheo B, Kang, Ling, Nawrocki, Andrea R, Zhou, Dan, Wu, Margaret, Previs, Stephen, Miller, Corey, Liu, Haiying, Hines, Catherine D G, Madeira, Maria, Cao, Jin, Herath, Kithsiri, Spears, Larry D, Semenkovich, Clay F, Wang, Liangsu, Kelley, David E, Li, Cai, Guan, Hong-Ping
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 03.10.2016; Public Library of Science (PLoS)
• Subjects: Animal models; Antibiotics; Bacteria; Biology and Life Sciences; Biomarkers; Carbohydrates; Carnitine; Carnitine palmitoyltransferase; Cynomolgus; Diabetes; Diabetes mellitus; Diabetes therapy; Diet; Disease; Enzymes; Fatty acid synthesis; Fatty acids; Fatty liver; Fatty-acid synthase; Glucose; Glucose metabolism; Glycolysis; Health aspects; Inhibition; Inhibitors; Insulin; Insulin resistance; Laboratories; Lipids; Lipogenesis; Liver; Medicine and Health Sciences; Metabolic disorders; Metabolism; Mice; Monkeys; Nutrition research; Oral administration; Oxidation; Palmitoyltransferase; Perfusion; Pharmacology; Physical Sciences; Physiological aspects; Primates; Quantitation; Reduction; Research and Analysis Methods; Rodents; Steatosis; Streptomyces platensis; Synthesis; Triglycerides; Vaccines; United States > US
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0164133

Platensimycin (PTM) is a natural antibiotic produced by Streptomyces platensis that selectively inhibits bacterial and mammalian fatty acid synthase (FAS) without affecting synthesis of other lipids. Recently, we reported that oral administration of PTM in mouse models (db/db and db/+) with high de novo lipogenesis (DNL) tone inhibited DNL and enhanced glucose oxidation, which in turn led to net reduction of liver triglycerides (TG), reduced ambient glucose, and improved insulin sensitivity. The present study was conducted to explore translatability and the therapeutic potential of FAS inhibition for the treatment of diabetes in humans. We tested PTM in animal models with different DNL tones, i.e. intrinsic synthesis rates, which vary among species and are regulated by nutritional and disease states, and confirmed glucose-lowering efficacy of PTM in lean NHPs with quantitation of liver lipid by MRS imaging. To understand the direct effect of PTM on liver metabolism, we performed ex vivo liver perfusion study to compare FAS inhibitor and carnitine palmitoyltransferase 1 (CPT1) inhibitor. The efficacy of PTM is generally reproduced in preclinical models with DNL tones comparable to humans, including lean and established diet-induced obese (eDIO) mice as well as non-human primates (NHPs). Similar effects of PTM on DNL reduction were observed in lean and type 2 diabetic rhesus and lean cynomolgus monkeys after acute and chronic treatment of PTM. Mechanistically, PTM lowers plasma glucose in part by enhancing hepatic glucose uptake and glycolysis. Teglicar, a CPT1 inhibitor, has similar effects on glucose uptake and glycolysis. In sharp contrast, Teglicar but not PTM significantly increased hepatic TG production, thus caused liver steatosis in eDIO mice. These findings demonstrate unique properties of PTM and provide proof-of-concept of FAS inhibition having potential utility for the treatment of diabetes and related metabolic disorders.